MedPath

AZIDUS BRASIL PESQUISA CIENTIFICA E DESENVOLVIMENTO LTDA

🇧🇷Brazil
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19

Phase 3
Recruiting
Conditions
covid19
Interventions
Drug: Placebo
First Posted Date
2020-06-09
Last Posted Date
2022-10-31
Lead Sponsor
Azidus Brasil
Target Recruit Count
380
Registration Number
NCT04423861
Locations
🇧🇷

Hospital Vera Cruz, Campinas, São Paulo, Brazil

Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients

Phase 1
Conditions
COVID-19
Interventions
First Posted Date
2020-04-20
Last Posted Date
2020-04-29
Lead Sponsor
Azidus Brasil
Target Recruit Count
42
Registration Number
NCT04352465
Locations
🇧🇷

Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil

Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19

Early Phase 1
Suspended
Conditions
Covid-19
Interventions
First Posted Date
2020-04-16
Last Posted Date
2022-11-04
Lead Sponsor
Azidus Brasil
Target Recruit Count
200
Registration Number
NCT04348474
Locations
🇧🇷

Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil

Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

Not Applicable
Completed
Conditions
COVID-19
Interventions
Drug: Placebo
First Posted Date
2020-04-16
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Target Recruit Count
50
Registration Number
NCT04348409
Locations
🇧🇷

Hospital Vera Cruz, Campinas, São Paulo, Brazil

🇧🇷

Centro de Genomas, São Paulo, Brazil

🇧🇷

Hospital Emílio Ribas, São Paulo, Brazil

Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19

Early Phase 1
Suspended
Conditions
COVID-19
Interventions
First Posted Date
2020-04-01
Last Posted Date
2022-11-07
Lead Sponsor
Azidus Brasil
Target Recruit Count
400
Registration Number
NCT04329572
Locations
🇧🇷

Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil

NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

Phase 2
Completed
Conditions
COVID-19 Pneumonia
Interventions
Biological: Placebo
Biological: NestaCell®
First Posted Date
2020-03-20
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Target Recruit Count
90
Registration Number
NCT04315987
Locations
🇧🇷

Hospital de Barueri, São Paulo, Brazil

🇧🇷

IncCOR, São Paulo, Brazil

🇧🇷

UNIFESP, São Paulo, Brazil

and more 1 locations

Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.

Phase 2
Active, not recruiting
Conditions
Huntington Disease
Interventions
Biological: Cellavita-HD
First Posted Date
2020-01-07
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Target Recruit Count
35
Registration Number
NCT04219241
Locations
🇧🇷

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil

Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

Phase 1
Completed
Conditions
Renal Insufficiency, Chronic
Interventions
First Posted Date
2018-06-28
Last Posted Date
2022-11-03
Lead Sponsor
Azidus Brasil
Target Recruit Count
40
Registration Number
NCT03572647
Locations
🇧🇷

LAL Clínica Pesquisa e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil

Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease

Phase 2
Completed
Conditions
Huntington Disease
Interventions
Biological: Cellavita HD higher dose
Biological: Cellavita HD lower dose
Other: Placebo
First Posted Date
2017-08-17
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Target Recruit Count
35
Registration Number
NCT03252535
Locations
🇧🇷

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil

Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease

Phase 1
Active, not recruiting
Conditions
Huntington Disease
Interventions
Biological: Cellavita HD Lower Dose
Biological: Cellavita HD Higher dose
First Posted Date
2016-04-05
Last Posted Date
2022-11-02
Lead Sponsor
Azidus Brasil
Target Recruit Count
6
Registration Number
NCT02728115
Locations
🇧🇷

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy